)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Shelter Pharma
Shelter Pharma (543963) investor relations material
Shelter Pharma Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary7 Nov, 2026
Executive summary
H1 FY27 revenue rose 35.6% YoY to ₹451.3 million; PAT increased 15.4% to ₹51.9 million. Both revenue and margin guidance for FY27 remained on track.
H1 was the largest six-month period to date; revenue equaled 61.7% of FY26 sales, while exports matched FY26's full-year level in six months.
Financial highlights
Revenue from operations was ₹4,513.22 lakh versus ₹3,329.29 lakh in H1 FY26 and ₹3,984.07 lakh in H2 FY26; total income was ₹4,514.81 lakh.
PAT was ₹520.61 lakh versus ₹450.07 lakh YoY and ₹452.65 lakh HoH; PBT was ₹695.80 lakh.
EBITDA increased 17.9% YoY and 14.2% HoH to ₹73.8 million; EBITDA margin was 16.4%, down 244 bps YoY and up 13 bps HoH.
Gross margin was 22.6%, down 237 bps YoY and 57 bps HoH; PAT margin was 11.5%, down 201 bps YoY and up 15 bps HoH.
Employee costs rose 59.7% YoY to ₹13.6 million amid sales and export hiring; depreciation doubled to ₹3.8 million following capitalization of the new Himmatnagar building.
Outlook and guidance
FY27 guidance: revenue growth of 35–40%, EBITDA margin of 16–18%, and PAT margin of 11–13%; H1 performance was stated to be on track.
H2 is seasonally the larger half; FY30 revenue target is ₹2,000 million, representing a stated 28.6% CAGR from FY26 revenue of ₹731.3 million.
The second plant is expected to begin production from mid-to-end 2028; two-shift Himmatnagar operations and the new plant are intended to support the FY30 target.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Shelter Pharma
- Revenue and net profit rose in FY18; profits were retained and no dividend recommended.543963
Q4 17/18 - Revenue declined, but FY19 net profit and EPS improved; no dividend was recommended.543963Q4 18/19
- Revenue and PAT rose in FY20 as factory expansion advanced; Rs 3 crore of advances were written off.543963Q4 19/20
- COVID disruption cut sales as FY21 profit fell; ₹30 lakh of old advances was written off.543963Q4 20/21
- FY22 revenue and profit rose sharply, while COVID disruptions remained a sales risk.543963Q4 21/22
- FY23 profit rose, while receivables climbed and an IPO of up to ₹350m advanced.543963Q4 22/23
- Strong revenue and profit growth, full utilization of raised funds, and clean audit opinion.543963Q4 25/26
- Revenue and profit increased year-over-year, with all raised funds used as intended.543963Q2 25/26
- Revenue and net profit grew year-over-year, with EPS rising to ₹3.06.543963Q2 24/25
Next Shelter Pharma earnings date
Q3 26/276 Feb, 2027
Shelter Pharma
Next Shelter Pharma earnings date
Q3 26/276 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Shelter Pharma Ltd is a pharmaceutical company engaged in the manufacturing and marketing of Ayurvedic and herbal medicinal products. The company produces a variety of formulations including tablets, syrups, powders, oils, and ointments across therapeutic areas such as liver care, kidney care, women's health, and general wellness. It serves both domestic and international markets, with operations based on traditional Ayurvedic principles and supported by in-house research and quality control. Shelter Pharma Ltd is headquartered in Himmatnagar, India, and its shares are listed on the BSE.